Purpose Developing Your Own Blended Microbiome Therapeutics (YOBMT) by isolating and securing candidate microorganisms derived from the intestines of Korean for improving metabolic/immune diseases. Bacterial/viral genome analysis according to metabolic/immune disease occurrence and identification of mechanisms involved. Discovering the Inflammatory bowel disease and metabolic/immune disease induction/inhibition related symbiotic microbial agents and microbial community regulator. Identifying symbiotic microbial characteristics related to Inflammatory bowel disease onset/inhibition through multiomics analysis and investigation of human interaction mechanisms Contents Discovering major symbiotic microbes with functions about metabolic/immune control from Koreans (normal persons and metabolic/immune disease persons) and verifying their functions. By identifying antibiotics metabolism/immune functions and the interaction between intestinal microbes, tracking the microbial species harboring effective role to inhibit specific disease onset and establishing a network between microbes. Developing microbial regulators for improving disease by characterizing the interactions with virus-host microbes or virus-hosts in metabolic/immune diseases and inflammatory bowel diseases through intestinal viruses known as major members along with enteric bacteria. Based on the mechanism of action of intestinal microbes involved in the occurrence of metabolic/immune diseases, we produce the symbiotic microbial mixtures able to improve/control diseases, and discover the genes and peptides that can control microbial communities. Benefits By developing a symbiotic microbial preparation-based therapeutic agent, it provides an efficient and effective treatment compared to the treatment of metabolic/immune diseases focused on drugs that are recognized as foreign substances in the body. By discovering interaction factors between host-microorganisms and microorganisms, it can be used as a basic technology for the development of new-concept customized therapeutics for various diseases that are mediated by intestinal microflora. It can be subsequently used for symbiotic microbial-human interaction studies through host-microorganism database construction.